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Expansion of CAG repeats, which code for the disease-causing polyglutamine protein,
is a common feature in polyglutamine diseases. RNA-mediated mechanisms that
contribute to neuropathology in polyglutamine diseases are important. RNA-toxicity
describes a phenomenon by which the mutant CAG repeat RNA recruits RNA-binding
proteins, thereby leading to aberrant function. For example the MID1 protein binds to
mutant huntingtin (HTT ) RNA, which is linked to Huntington’s disease (HD), at its CAG
repeat region and induces protein synthesis of mutant protein. But is this mechanism
specific to HD or is it a common mechanism in CAG repeat expansion disorders? To
answer this question, we have analyzed the interaction between MID1 and three other
CAG repeat mRNAs, Ataxin2 (ATXN2), Ataxin3 (ATXN3), and Ataxin7 (ATXN7), that all
differ in the sequence flanking the CAG repeat. We show that ATXN2, ATXN3, and
ATXN7 bind to MID1 in a CAG repeat length-dependent manner. Furthermore, we show
that functionally, in line with what we have previously observed for HTT, the binding
of MID1 to ATXN2, ATXN3, and ATXN7 mRNA induces protein synthesis in a repeat
length-dependent manner. Our data suggest that regulation of protein translation by the
MID1 complex is a common mechanism for CAG repeat containing mRNAs.
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INTRODUCTION
CAG repeat expansion diseases are the most common forms of inherited neurodegenerative
diseases. They are caused by expansion mutations of the trinucleotide CAG in the respective
disease-causing genes. These genes are functionally unrelated and the only common motif of
these genes is the CAG repeat. If the CAG repeat is located within the protein-coding region
it encodes a polyglutamine stretch. Intraneuronal aggregation of the polyglutamine proteins is
a pathological hallmark of several CAG repeat diseases and the production of polyglutamine
proteins is linked to neurotoxicity (Rudnicki and Margolis, 2003; Shao and Diamond, 2007;
Fiszer and Krzyzosiak, 2014). In addition to neurotoxic effects of polyglutamine protein, there is
emerging evidence showing that RNA-mediated mechanisms also contribute to neurotoxicity in
polyglutamine diseases (reviewed in Nalavade et al., 2013 and Schilling et al., 2016).
Structurally, RNAs with expanded CAG repeats fold into hairpin structures in vitro and these
hairpins increase in size and stability with increasing CAG repeat numbers (Sobczak et al.,
2003; Sobczak and Krzyzosiak, 2005; Kiliszek et al., 2010; de Mezer et al., 2011). These RNA
Griesche et al. MID1 Regulates CAG Repeat RNAs
molecules with expanded CAG repeats can execute abnormal
functions by recruiting different RNA binding proteins leading
to the loss of normal function of these proteins and/or
inducing aberrant function of these proteins when bound to
the CAG repeat RNA (reviewed in Nalavade et al., 2013).
For example, there is evidence that polyglutamine protein
synthesis from expanded CAG repeat mRNAs is increased
compared to CAG repeat mRNAs with normal repeat lengths
(Krauss et al., 2013). Of note, this affects not only the
polyglutamine protein, but additionally also homopolymeric
expansion proteins are produced from expanded CAG repeat
mRNA in all three reading frames without an AUG start codon
by RAN translation (repeat-associated non-ATG translation)
(Bañez-Coronel et al., 2015). Based on the neurotoxic function of
all these protein species produced from expanded CAG repeats,
a reduction of these proteins will be beneficial in the disease
context. In accordance, reduction of polyglutamine protein in
disease models for polyglutamine diseases improved the disease
phenotype (Yamamoto et al., 2000; Boudreau et al., 2009; Zhang
and Friedlander, 2011). But how is the increased protein synthesis
rate from expanded CAG repeat mRNAs regulated?
One mechanism that we have recently identified to play a role
in regulating the translation of huntingtin (HTT) mRNA with
expanded CAG repeats involves the MID1-protein phosphatase
2A (PP2A) complex (Krauss et al., 2013). MID1 is an E3 ubiquitin
ligase: upon binding to PP2A, MID1 catalyzes the ubiquitin-
dependent degradation of PP2A (Trockenbacher et al., 2001).
Thereby MID1 acts as a negative regulator of PP2A activity and
at the same time unleashes the activity of the PP2A opposing
kinase mTOR (Liu et al., 2011). mTOR and PP2A regulate the
phospho-dependent activity of S6K, a translational regulator.
Via MID1, S6K is recruited to the expanded CAG repeat motif
of HTT mRNA. This recruitment of the MID1 complex to the
expanded mutant HTT mRNA induces translation in a CAG
repeat length-dependent manner (Krauss et al., 2013).
Here we addressed the question of whether an MID1-
dependent increase in translation of expanded CAG repeat
mRNA is specific to HTT or if this is a common feature of
CAG repeat expansion disorders. mRNAs with expanded CAG
repeats can fold into hairpins (Sobczak et al., 2003; Michlewski
and Krzyzosiak, 2004; Kiliszek et al., 2010; de Mezer et al.,
2011). However, there is a CCG repeat down stream of the CAG
repeat of HTT that can stabilize this hairpin structure. A similar
CCG repeat is not present in other CAG repeat mRNAs, such
as Ataxin2 (ATXN2), Ataxin3 (ATXN3), or Ataxin7 (ATXN7).
In this study we show that MID1 can also bind to the CAG
repeat region of ATXN2, ATXN3, and ATXN7 in vitro, suggesting
that binding of MID1 to CAG repeats is not dependent on the
flanking regions. Furthermore, we show that this binding of
MID1 to ATXN2, ATXN3, and ATXN7 mRNA, similar to what
we have shown previously for HTT (Krauss et al., 2013), induces
translation in a CAG repeat length-dependent manner in vitro
and in cell lines. Our data suggest that MID1 is a common
regulator of CAG repeat mRNAs and thus may be a disease
modifier in CAG repeat expansion disorders. This observation
makes the MID1 complex an interesting putative therapeutic
target for the treatment of polyglutamine diseases.
METHODS
RNA-Protein-Co-Immunoprecipitation
Primary cortical neurons from a SCA3 mouse model [B6;CBA-
Tg(ATXN3∗)84.2Cce/IbezJ (JAX labs)] were prepared from
embryos at E14 as described previously (Kickstein et al., 2010).
These transgenicmice express humanmutant ATXN3 containing
84 CAG repeats. Cells were transfected with pCMVTag2a-MID1
using Lipofectamine 2000. 48 h after the transfection cells were
harvested, UV-crosslinked (300 J/cm2) and lysed in TKM buffer
(20 mM Tris, 50 mM KCl, 5 mM MgCl2). MID1-containing
RNA-protein complexes were purified by immunoprecipitation
using ANTI-FLAG M2 Affinity Gel (SIGMA-ALDRICH) or
Mouse IgG-Agarose (SIGMA-ALDRICH) as a negative control.
To isolate MID1-bound RNAs the immunoprecipitates were
treated with proteinase K for 30 min at 37◦C and RNA extraction
was performed by phenol/chloroform extraction followed by
ethanol precipitation. cDNA synthesis was performed using the
TaqMan Reverse transcription reagent kit (LifeTechnologies). As
a negative control, reverse transcriptase was not used (−RT).
PCR was performed using the following primers to amplify
human ATXN3: forward primer 5′-TGGCTCAATTACAACA
GGAAGGT-3′ and reverse primer 5′-TGGTCGATGCATCTGT
TGGA-3′ (PCR product 113 bp). Similarly, mouse embryonic
fibroblasts of a homozygous knock-in mouse model expressing
mutantATXN2with 42 CAG repeats (Damrath et al., 2012), were
subjected to MID1-immunprecipitation followed by extraction
of MID1-bound RNAs and RT-PCR analysis using primers for
ATXN2: forward primer 5′-GCATGTCCCAAATTACCATAC
AAC-3′ and reverse primer 5′-CCGGTGGAAATGGCAAAGTA
GA-3′ (PCR product 65 bp).
RNA Pulldown
ATXN2, ATXN3, or ATXN7 fragments containing the CAG
repeat plus flanking region with either normal or mutant repeat
lengths were PCR amplified (ATXN2-forward 5′-CCAAGCTTC
TAATACGACTCACTATAGGGAGACCTCACCATGTCGCTG
A-3′, ATXN2-reverse 5′-TGTTACTGTTTCGACCTCTGC-
3′; ATXN3-forward 5′-CCAAGCTTCTAATACGACTCACT
ATAGGGAGACCGCAGGGCTATTCAGCTAAG-3′, ATXN
3-reverse 5′-CAGCTGCCTGAAGCATGTCTT-3′; ATXN7-
forward 5′-CCAAGCTTCTAATACGACTCACTATAGGGAGA
GAATGTCGGAGCGGGCCG-3′, ATXN7-reverse 5′-CCCAGC
ATCACTTCAGGACT-3′). As templates plasmids containing
the complete cDNA of the different ATXNs from either SCA
patients or healthy individuals were used. The repeat numbers
of the different cDNAs were: ATXN2 normal (CAG)8-CAA-
(CAG)4-CAA-(CAG)8, ATXN2 mutant (CAG)74, ATXN3
normal (CAG)15, ATXN3 mutant (CAG)-CAA-(CAG)40-
CGG-(CAG)21, ATXN7 normal (CAG)19,ATXN7 mutant
(CAG)43-CGG-(CAG)37. All forward primers contained the T7
promotor sequence to allow subsequent in vitro transcription
of the PCR product. Purified PCR products were in vitro
transcribed using the RiboMAX Express large scale RNA
production system-T7 (Promega) according to the manufacture’s
instructions with some modifications. Briefly, 2µg of purified
PCR product were transcribed for 4 h at 37◦C under the
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addition of biotinylated UTPs (Ambion). The resulting in
vitro transcribed RNA was purified by phenol/chloroform
extraction followed by ethanol precipitation. MID1-FLAG
was overexpressed in HeLa cells. Cells were lysed in TKM
buffer and lysates were incubated with the in vitro transcribed
RNA. Subsequently, the mixture was incubated with M280
streptavidin coated magnetic beads (Thermo Fisher). After
extensive washing, RNA-bound proteins were eluted by boiling
the beads in 80 µl sample buffer (48% urea, 15 mM Tris-HCL
pH 7.5, 8.7% glycerine, 1% SDS, 0.004% Bromophenolblue,
143 mM Mercaptoethanol), for 10 min at 95◦C. RNA-bound
proteins were then analyzed on western blots using ANTI-FLAG
M2-Peroxidase (HRP) antibody (SIGMA, A8592) to detect
FLAG-MID1.
In Vitro Translation
Firefly luciferase constructs fused to ATXN2, ATXN3, or ATXN7
fragments containing the CAG repeat plus flanking region with
either normal or mutant repeat lengths were PCR amplified
using the following primers: Luci T7 for 5′-CCAAGCTTCTAAT
ACGACTCACTATAGGGAGAATGGAAGACGCCAAAAACA
TA-3′; ATXN2-reverse 5′-TGTTACTGTTTCGACCTCTGC-
3′; ATXN3-reverse 5′-CAGCTGCCTGAAGCATGTCTT-3′;
ATXN7-reverse 5′-CCCAGCATCACTTCAGGACT-3′. As
templates Plasmids with the different ATXN fragments described
in the section for luciferase assays were used. All forward primers
contained the T7 promotor sequence to allow subsequent in vitro
transcription of the PCR product. The PCR products were in vitro
transcribed using the T7 RiboMAX
TM
Express Large Scale RNA
Production System (Promega). After phenol/chloroform
extraction and subsequent ethanol precipitation of the resulting
RNA an in vitro translation reaction, using the Flexi Rabbit
Reticulocyte Lysate System (Promega), was performed. The
amount of in vitro translated firefly luciferase was measured in
a luciferase assay using the protocol described below without
the Stop and Glow reaction. As a positive control we included
previously published constructs (Krauss et al., 2013) with HTT
exon1 fused to luciferase, and as a negative control we used a
sample without RNA.
Luciferase Assays
For the Luciferase assays HEK293T cells were used. Cells
were cultivated in DMEM medium (Gibco) containing 10%
FCS (PAN) and Pen/Strep. Cells were tested semi-annually for
mycoplasma using the Mykoplasma Kit from Promokine (PK-
CA91-1096). Cells were transfected with psiCheck2-constructs in
which short ATXN2, ATXN3, and ATXN7 sequences containing
either normal or mutant CAG repeats were cloned into
the 3′-UTR of firefly luciferase. This allows the analysis of
effects mediated by CAG repeats in the mRNA without being
translated into polyglutamine stretches fused to the luciferase.
This is important since polyglutamine stretches might make the
luciferase insoluble and might therefore influence its activity.
On the same vector backbone there is a renilla luciferase gene,
which is used as internal transfection control. Additionally, we
created constructs in which pure CAG or CAA repeats (50
repeats each), were fused to renilla luciferase in the psiCheck2
vector. In these plasmids firefly luciferase served as an internal
transfection control. 24 h after transfection cells were lysed in
passive lysis buffer (Promega). For the luciferase measurements
the Dual luciferase assay kit (Promega) was used. In brief, in
a first step a substrate for firefly luciferase (LARII) was added
to the lysates and the relative light units were measured. After
the measurement of the firefly luciferase, an equal amount
of renilla substrate (Stop and Glo buffer) was added to the
samples. After a 2 s delay, renilla luciferase was measured.
Mean values of relative light units ± SEM were calculated.
The average of the ATXN2, ATXN3, and ATXN7 samples with
normal CAG repeats was set to 100%. Statistics were done using
t-test.
MID1 Knock Down
1 × 105 HEK293T cells per well of a 24 well plate were seeded 1
day prior transfection. Cells were transfected with 2.5 µl of a 20
µM stock of either a pool of four siRNAs targeting MID1 (TTG
AGTGAGCGCTATGACAAA, AAGGTGATGAGGCTTCGC
AAA, CACCGCAUCCUAGUAUCACACTT, CAGGAUUAC
AACUUUUAGGAATT) or a non-silencing control siRNA (AAT
TCTCCGAACGTGTCACGT) per well using Oligofectamine
(ThermoFisher) according to the manufacturer’s instructions.
After 24 h cells were transfected with the psiCheck2 constructs
described above with Lipofectamine 2000 (ThermoFisher)
according to the manufacturer’s instructions. After another 24
h cells were harvested in passive lysis buffer (Promega). Dual
luciferase assays were performed as described above. Average
values of the relative light units normalized to the internal
transfection control are shown. The resulting values were
normalized to the relative light units of control samples, in which
empty psiCheck2 vector was co-transfected with the respective
siRNAs. Statistics were done using t-test.
Fluorescence Recovery after
Photobleaching (FRAP) Based Assay to
Monitor Translation
To monitor the translation rate of the different CAG repeat
mRNAs with a previously established FRAP based technique
in living cells (Krauss et al., 2013), we cloned the sequence
of enhanced green fluorescent protein (EGFP) into the pBUD-
CE4 vector backbone. 3′ of the EGFP sequence behind the
stop codon in the untranslated region, we cloned the short
ATXN2 or 3 sequences containing either normal or mutant
CAG repeats described in Supplementary Table 1. For the
FRAP-based assays HELA cells were used. Cells were cultivated
in DMEM medium (Gibco) containing 10% FCS (PAN) and
Pen/Strep. Cells were tested semi-annually for mycoplasma using
the Mykoplasma Kit from Promokine (PK-CA91-1096). 1 ×
103 HeLa cells per well were grown on microscopy 8-well
chamber slides and were transfected with these constructs using
Polyfect (Qiagen) according to the manufacturer’s instructions.
20 h after transfection cells were analyzed with an LSM700
microscope from Zeiss using a X20 objective. Individual cells
were chosen and the GFP signal was bleached with a high
intensity 488 argon laser. After bleaching the GFP signal was
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imaged every 5 min for 4 h. For the analysis the GFP signal
of every cell was analyzed as the sum of the pixel over the
area of the cell. To normalize the results of each cell, the
second frame after bleaching was set as point zero and put to
100%.
Western Blot
Cell pellets of a fibroblast cell line of a previously described
SCA3 patient (MJD1) with 74/22 CAG repeats in the ATXN3
gene (Koch et al., 2011) were analyzed. Protein extracts were
dissolved sample buffer (48% urea, 15 mM Tris-HCL pH 7.5,
8.7% glycerine, 1% SDS, 0.004% Bromophenolblue, 143 mM
Mercaptoethanol), boiled for 20 min at 95◦C, separated on 4–
20% Mini-PROTEAN TGX Precast Protein Gels (Bio-Rad) and
western blotted onto PVDF membranes (Roche). ATXN3 was
detected using anti-ATXN3 antibodies (Millipore, MAB5360)
and actin (Cell signaling, 4967L) was detected as loading control.
Bands on the western blots were analyzed in triplicates and
quantified using Fiji Software. Data shown represent mean
± SEM. Statistical significances were evaluated using t-test
(twotailed, homoscedastic).
Prediction of RNA Secondary Structures
Prediction of RNA secondary structure was performed using
the mfold Web Server (http://unafold.rna.albany.edu/?q=mfold)
(Mathews et al., 1999; Zuker, 2003). To determine secondary
RNA structures the parameters were set to assume a 1M NaCl
solution, 37◦C and a linear sequence. Free energy contributions
of the folding were counted and are listed.
RESULTS
MID1 Binds to Several CAG Repeat RNAs
MID1 binds to HTT mRNA at its CAG repeat region and
induces its translation (Krauss et al., 2013). To test if the
flanking regions influence the binding of MID1 to CAG repeat
mRNAs, we tested the binding of MID1 to ATXN2, ATXN3, and
ATXN7 mRNAs. We performed RNA-protein binding assays, in
which in vitro transcribed ATXN2, ATXN3, and ATXN7 RNA-
constructs with either normal or mutant CAG repeat lengths
were used. For a detailed description of the RNA sequences
and the predicted RNA folding see Supplementary Figure 1 and
Supplementary Table 1. These in vitro transcribed RNAs were
immobilized on magnetic beads and incubated with protein
extracts containing FLAG-MID1 to allow RNA-protein binding.
After extensive washing,MID1 that bound to respective RNAwas
analyzed on a western blot using FLAG-antibodies. In all three
cases, we observed that (i)MID1 did bind to the CAG repeat RNA
and (ii) this binding was stronger in the samples with expanded
CAG repeats (Figure 1A). This experiment suggests that the
MID1 protein complex binds to CAG repeat RNAs independent
of the flanking regions. To further establish this and to test for
the functional relevance of this with an RNA that is naturally
processed (e.g., transcribed, spliced, etc.) and that is linked to
a polyglutamine disease, we performed experiments on ATXN3
FIGURE 1 | MID1 binds to CAG repeat RNAs irrespective of the repeat-flanking sequences. (A) The binding of three different CAG repeat RNAs to MID1 was
analyzed. Upper panel: schematic showing the predicted hairpin folding as well as the different CAG repeat flanking regions of ATXN2, ATXN3, and ATXN7 to visualize
the different RNA fragments that were used, different colors symbolize the different flanking regions. Lower panel: in vitro transcribed fragments of ATXN2, ATXN3, and
ATXN7 containing either normal or mutant CAG repeats were incubated with MID1-FLAG containing lysates. RNA-bound MID1 protein was analyzed on western blot
using FLAG-antibodies. A representative western blot of n = 3 experiments is shown. (B) RNA-immunoprecipitation was performed in lysates from either mouse
embryonic fibroblasts expressing mutant ATXN2 or primary neurons of a SCA3 mouse model that expresses full-length human ATXN3 with a mutant CAG repeat.
MID1 was immunopurified and the presence of ATXN2 (upper panel) or human ATXN3 (lower panel) in the MID1 complex was tested by RT-PCR on RNA that
co-purified with MID1. As negative control, a sample with unspecific IgG was used. As additional negative control a–RT reaction was performed. RT-PCR products
were analyzed on an agarose gel. A representative gel of n = 3 experiments is shown.
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using neurons from a SCA3 mouse model and experiments on
ATXN2 using mouse embryonic fibroblasts of a SCA2 mouse
model. To test if MID1 binds to endogenously transcribed
full-length mutant ATXN2mRNA, we expressed FLAG-MID1 in
mouse embryonic fibroblasts of a homozygous knock-in mouse
model expressingmutantATXN2with 42 CAG repeats (Damrath
et al., 2012). From these cells MID1-protein complexes were
immunopurified and MID1 bound RNAs were isolated. The
presence of ATXN2 mRNA in the MID1-immunoprecipitates
were then analyzed by RT-PCR. Similarly, to test if MID1 binds
to endogenously transcribed full-length mutant ATXN3 mRNA,
we expressed FLAG-MID1 in primary neurons of a transgenic
mouse line that expresses full-length mutant human ATXN3.
From these cells MID1-protein complexes were immunopurified
and MID1 bound RNAs were isolated. The presence of mutant
human ATXN3 mRNA in the MID1-immunoprecipitates were
then analyzed by RT-PCR using primers specific for human
ATXN3. In line with the data from the RNA-protein pulldown,
we clearly observed binding between MID1 and full-length
mutant ATXN3 mRNA as well as full-length ATXN2 mRNA
(Figure 1B).
Translation of Mutant ATXN2, ATXN3, and
ATXN7 Is Increased
In previous studies we observed that the translation rate of
HTT increases with increasing CAG repeat length (Krauss
et al., 2013). Therefore, we asked if similarly the translation
of ATXN2, ATXN3, and ATXN7 with mutant compared to
normal CAG repeat length is increased. To test this, we
performed an in vitro translation assay. For this, luciferase
reporter constructs containing ATXN2, ATXN3, and ATXN7
with either normal or mutant CAG repeat lengths in the 3′
UTR were in vitro transcribed. The position of the ATXN
fragments in the 3′UTR was chosen to allow detection of
regulatory effects of the CAG repeats on the RNA level without
being translated into polyglutamine stretches on the protein
level (Figure 2A). Equimolar amounts of the resulting in vitro
transcribed RNAs were then used in an in vitro translation
reaction. The level of luciferase reporter that was translated
was measured in a luciferase assay. As a positive control we
included previously published constructs (Krauss et al., 2013)
with HTT exon1 fused to luciferase, and as a negative control
we used a sample without RNA. The translation rate of the
reporter-containing mutant ATXN2, ATXN3, and ATXN7 was
significantly increased compared to the constructs with normal
repeat length (Figure 2B). In a second set of experiments, we
used constructs containing a firefly luciferase reporter with the
CAG repeat region of ATXN2, ATXN3, and ATXN7 in the
3′UTR and renilla luciferase as an internal transfection control to
transfect HEK293T cells and measure the protein level produced
in living cells. In line with our observation from the in vitro
translation, the level of the luciferase translated from the ATXN2,
ATXN3, and ATXN7 mutant RNA was significantly increased
compared to the normal control (Figure 3A). Additionally we
performed a previously established FRAP-based assay that allows
monitoring of translation in living cells (Krauss et al., 2013). In
brief, GFP-constructs containing ATXN2 or ATXN3 with either
normal or mutant CAG repeat lengths in the 3′ UTR were
transfected into HeLa cells. After bleaching of the GFP protein
in the entire cell, we measured GFP-signal recovery, which
corresponds to newly synthesized protein over a time frame of
4 h. To control that the GFP-signal recovery indeed represents
freshly translated protein, we performed experiments with the
translation inhibitor cycloheximide (CHX). In line with the data
from the luciferase assay, we observed a significantly increased
translation rate of mutant compared to normal ATXN2 and
ATXN3 (Figure 3B, Supplementary Figure 2). Together these
data suggest that, similar to what we have seen for HTT (Krauss
et al., 2013), the translation rate of mutant ATXN2, ATXN3, and
ATXN7 is increased.
FIGURE 2 | Increased translation of ATXN2, ATXN3, and ATXN7 constructs with expanded CAG repeats in vitro. (A) Schematic showing luciferase reporter
constructs used in this experiment. Luciferase reporter constructs were cloned that contain the CAG repeat region of ATXN2, ATXN3, and ATXN7 in the 3′UTR. Two
constructs each with either normal (left) or mutant CAG (right) repeat lengths were cloned. (B) In vitro translation of the luciferase reporters of ATXN3. Previously
published HTT exon1 luciferase reporter constructs were included as positive controls (Krauss et al., 2013). The constructs with either normal or mutant CAG repeat
lengths were in vitro transcribed and equimolar amounts of RNA were subjected to in vitro translation. The level of translated luciferase reporter was measured in a
luciferase assay. Columns represent mean values ± SEM. n = 3, p ≤ 0.01. (C) In vitro translation of the luciferase reporters of ATXN2 and ATXN7. The constructs with
either normal or mutant CAG repeat lengths were in vitro transcribed and equimolar amounts of RNA were subjected to in vitro translation. The level of translated
luciferase reporter was measured in a luciferase assay. As a negative control, a sample without RNA was included. Columns represent mean values ± SEM. n = 3,
p ≤ 0.0001. *Indicates statistically significant differences (p < 0.05).
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FIGURE 3 | Enhanced translation of ATXN2, ATXN3, and ATXN7
constructs with expanded CAG repeats in cell lines. (A) Dual luciferase
reporter assay in HEK293T cells transfected with constructs containing a firefly
luciferase reporter with the CAG repeat region of ATXN2, ATXN3, and ATXN7
in the 3′UTR and renilla luciferase as an internal transfection control. Data
shown represent relative light units of the ATXN2, ATXN3, and ATXN7 firefly
luciferase construct normalized to renilla luciferase. The mean of the
constructs with normal CAG repeat length was set to 100%. Columns
represent mean values ± SEM. n = 6, p < 0.05 (B) Fluorescence recovery
after photobleaching assays to monitor translation were performed for
(Continued)
FIGURE 3 | Continued
ATXN2 and ATXN3 containing normal or mutant CAG repeat regions. HeLa
cells transfected with GFP-ATXN2 normal or mutant as well as GFP-ATXN3
normal or mutant were bleached with a high intensity laser. Translation is
monitored by analyzing the recovery of GFP signal in living cells over 4 h.
Negative controls are cells treated with the translational inhibitor
cycloheximide. Lines represent mean values over the time. Assays were
performed in triplicates with several cells per experiments (cells analyzed
altogether —ATXN2: nmutant = 17, nnormal = 12, nmutant CHX = 11,
nnormal CHX = 19; ATXN3: nmutant = 21, nnormal = 20, nmutant CHX = 16,
nnormal CHX = 18). Statistics were performed using two way anova (p <
0.0001). *Indicates statistically significant differences (p < 0.05).
MID1 Regulates Translation of CAG Repeat
mRNAs
In previous studies we observed that binding of the MID1-
complex to mutantHTT mRNA leads to an increased translation
(Krauss et al., 2013). Our finding that also the translation rate of
mutant ATXN2, ATXN3, and ATXN7 is increased led us to the
hypothesis that MID1 regulates and induces translation of CAG
repeat mRNAs irrespective of the repeat flanking sequence. To
test this hypothesis, we created luciferase constructs, which are
fused to pure CAG repeats in their 3′UTR. As a control we used
constructs with CAA repeats of similar length. These constructs
were transfected into HEK293T cells that underwent siRNA
mediated MID1-knockdown. To minimize off-target effects we
used a pool of four different siRNAs. Strikingly, MID1 depletion
reduced the translation of the construct with the pure CAG
repeat, while it did not influence the construct with the CAA
repeat (Figure 4A). To show if similar to the reporter with
pure CAG repeats, the increased translation of mutant ATXN2,
ATXN3, and ATXN7 is MID1 dependent we co-transfected the
above-mentioned luciferase reporters fused to mutant ATXN2,
ATXN3, and ATXN7 with or without MID1-specific siRNAs.
Indeed, depletion of MID1 led to a significant reduction in the
translation rate of the mutant ATXN2, ATXN3, and ATXN7
reporters (Figure 4B). Of note, while the translation of the
luciferase reporter with normal ATXN2was not affected byMID1
knockdown, both luciferase reporters with normal ATXN3 and
ATXN7 showed also decreased signals afterMID1 depletion (data
not shown). Together, all these observations suggest that MID1
binds to and regulates the translation of CAG repeat mRNAs
irrespective of the repeat flanking regions.
Since we observed stronger binding of MID1 to CAG
repeat constructs with expanded CAG repeats and an increased
translation rate of constructs with normal vs. mutant CAG
repeats, we asked if in patients with polyglutamine diseases
more protein is being produced from the mutant compared to
the normal allele. As an example for a polyglutamine disease,
we analyzed a patient derived cell line of a SCA3 patient. We
performed western blots analysis from a fibroblast cell line of a
SCA3 patient detecting ATXN3. A smaller band corresponding
to protein translated from the normal allele and a bigger
band corresponding to mutant ATXN3 protein, were detected.
Significantly more mutant than normal protein was detected
suggesting that the translation rate of RNA from themutant allele
is higher than from the normal allele in SCA3 patients (Figure 5).
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FIGURE 4 | Translation of CAG repeats but not CAA repeats is regulated by MID1. (A) Dual luciferase reporter assay in HEK293T cells co-transfected with
MID1 specific or control siRNAs and constructs containing a renilla luciferase reporter with pure CAG repeats or pure CAA repeats in the 3′UTR and firefly luciferase as
an internal transfection control. Data shown represent relative light units of renilla luciferase construct normalized to firefly luciferase. Columns represent mean values
± SEM. n = 3, p < 0.0001. (B) Dual luciferase reporter assay in HEK293T cells co-transfected with MID1 specific or control siRNAs and constructs containing a firefly
luciferase reporter with the CAG repeat region of ATXN2, ATXN3, and ATXN7 in the 3′UTR and renilla luciferase as an internal transfection control. Data shown
represent relative light units of the ATXN2, ATXN3, and ATXN7 firefly luciferase construct normalized to renilla luciferase. Values were normalized to mean values of
empty vectors co-transfecetd with the respective siRNA. Columns represent mean values ± SEM. n = 6, p < 0.0001. To show knockdown efficiency MID1 (upper
panel) and actin (lower panel, loading control) were detected on a western blot using specific antibodies. *Indicates statistically significant differences (p < 0.05).
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FIGURE 5 | Increased translation of mutant ATXN3 in SCA3 fibroblasts.
(A) Western blot analysis of extracts from fibroblasts derived from a SCA3
patient carrying 74/22 CAG repeats in the ATXN3 gene is shown. Two ATXN3
bands were detected, one smaller translated from the normal, one bigger
translated from the mutant allele. Actin was analyzed as control. (B)
Quantifications of bands (protein expressed from the normal compared with
protein expressed from the mutant allele) from (A) are shown. Mean values ±
SEM are shown, n= 3, p < 0.0001. *Indicates statistically significant
differences (p < 0.05).
DISCUSSION
Different molecular mechanisms have been discovered to play
a role in polyglutamine diseases including RNA-mediated
mechanisms. One of these mechanisms is the recruitment of the
MID1 protein complex to expanded CAG repeats in the HTT
mRNA (Krauss et al., 2013). MID1 binds to HTT mRNA with
pathologically expanded CAG repeats and recruits a translational
machinery, thereby inducing translation of mutant HTT mRNA
(Krauss et al., 2013). In this study, we asked if this binding and
translational regulation by MID1 is specific forHTT or if this is a
common mechanism involved in several CAG repeat diseases. In
summary, all our data suggest that MID1 binds to diverse CAG
repeat mRNAs, independent of the flanking regions, and that this
binding is accompanied by translational induction (Figure 6).
CAG repeat RNA folds into hairpin structures (Sobczak et al.,
2003; Busan and Weeks, 2013). These hairpins fold due to
Watson-Crick base-pairing at the G-C and C-G base pairs of
the CAG sequence, interrupted by an A-A wobble (Sobczak
et al., 2003; Kiliszek et al., 2010). The sequence adjacent to the
CAG repeat, the flanking region, influences the folding of the
hairpin structure. For example, in the HTT mRNA the CAG
repeat borders on a CCG repeat that interacts with the CAG
repeat and stabilizes the hairpin structure (de Mezer et al., 2011).
In contrast, the ATXN2, ATXN3, and ATXN7mRNAs do not
contain such a hairpin-stabilizing CCG motif and these CAG
repeats fold into slippery hairpins, i.e., hairpins of different
length exist (Michlewski and Krzyzosiak, 2004; Sobczak and
Krzyzosiak, 2005). The CAG repeat hairpin structures are known
to interact with certain proteins, whereupon more protein is
bound by expanded CAG repeats (McLaughlin et al., 1996). This
recruitment of protein to the mutant CAG repeat mRNA can
lead to a loss of normal function or an abnormal function of
the respective RNA-binding protein. For example muscleblind-
like 1 protein (MBNL1), which normally regulates splicing of its
target mRNAs, is recruited to elongated CAG repeats leading to
misregulation of splicing (Yuan et al., 2007; Mykowska et al.,
2011). Other examples are sequestration of nucleolin, leading
to reduced cellular rRNA (Tsoi et al., 2012; Tsoi and Chan,
2013) and sequestration of proteins of the siRNA machinery,
resulting in the production of short silencing RNAs that affect
gene expression (Krol et al., 2007; Bañez-Coronel et al., 2012).
Another example that we have shown before is the MID1
protein. Amongst other functions MID1 regulates translation of
its target mRNAs (Aranda-Orgillés et al., 2011; Hettich et al.,
2014; Köhler et al., 2014). MID1 is recruited to the CAG repeats
of mutant HTT mRNA in a repeat length-dependent manner,
which leads to increased translation of mutant HTT (Krauss
et al., 2013). In this study we asked the question if the flanking
regions of the CAG repeat, and their impact on the folding of
the hairpin structure, influence the binding of MID1 to CAG
repeat mRNAs. We show here that MID1 binds to elongated
CAG repeats flanked by sequences of ATXN2, ATXN3, and
ATXN7. This leads us to the conclusion that MID1 is recruited
to mutant CAG repeat mRNAs independent of the flanking
regions.
MID1 regulates translation of a number of target mRNAs
(Aranda-Orgillés et al., 2011; Hettich et al., 2014; Köhler et al.,
2014). For example, MID1 binds to BACE1 mRNA and induces
its translation linking translational regulation by MID1 to
Alzheimer’s Disease (Hettich et al., 2014). Other targets of MID1-
regulated translation are the PDPK-1 and androgen receptor
(AR) mRNAs (Aranda-Orgillés et al., 2011; Köhler et al., 2014).
Furthermore, the binding of the MID1 complex to mutant HTT
mRNA leads to an initiation of translation via themTOR pathway
(Krauss et al., 2013). Based on this observation we asked if
binding of MID1 to other CAG repeat mRNAs also increases
translation.We show in this study, for the first time, evidence that
ATXN2,ATXN3, andATXN7 are novel targets ofMID1. Our data
suggest that translation ofmutantATXN2,ATXN3, andATXN7 is
similar to what we have previously seen for HTT, upregulated by
MID1. MID1 binds to CAG repeat mRNAs in a length dependent
manner. Interestingly, binding is weak to transcripts with CAG
repeats of normal length, as they occur in healthy individuals.
However, we observed a reduced translation of constructs with
normalATXN3 andATXN7 afterMID1 depletion. Therefore, it is
possible that one physiological function ofMID1 is the regulation
of a moderate translation of CAG repeat mRNAs. However, in
diseases where the CAG repeat is expanded, the binding of MID1
is increased, thus leading to an aberrantly increased translation
rate.
In polyglutamine diseases several pathogenic mechanisms
seem to exist in parallel and to act in concert causing
neurotoxicity in a specific subgroup of neurons in patient brains.
These include protein—and RNA-based mechanisms (reviewed
in Nalavade et al., 2013). In a Drosophila model of SCA3 the
interspersal of CAA within the CAG repeat (both codons code
for glutamine) results in mitigated toxicity (Li et al., 2008). This
observation shows that the polyglutamine protein is neurotoxic,
but neurotoxicity is increased if a CAG repeat hairpin is present
on the RNA level. Our data show that MID1 binds to the
CAG repeats above a certain threshold, presumably the threshold
where folding into hairpin structures occurs. SinceMID1 induces
the translation of neurotoxic polyglutamine protein this could be
one explanation why pure CAG repeat mRNAs seem to be more
toxic than mixed CAG-CAA mRNAs.
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FIGURE 6 | MODEL. Model showing the interaction between the MID1 complex and CAG repeat mRNAs (adapted from Nalavade et al., 2013). The MID1 complex
binds to CAG repeats independent of its flanking region and recruits its binding partners, including S6K to the RNA. S6K is a translational regulator with
phospho-dependent activity that is regulated by PP2A and mTOR. MID1 not only acts as a scaffold bridging the binding between mRNA and S6K, but it also
regulates the activity of PP2A and mTOR. Thereby, MID1 is able to induce translation of mRNA.
Another mechanism by which expanded CAG repeat mRNAs
are translated at an increased rate is the so-called repeat-
associated non-ATG (RAN) translation. By this mechanism not
only is the polyglutamine protein translated from the CAG repeat
mRNA starting at the regular AUG initiation codon, but also
additional protein species that are translated directly starting
at the CAG repeat without the need of an AUG start codon
are produced (Zu et al., 2011; Bañez-Coronel et al., 2015). An
additional mechanism that leads to the translation of polyalanine
and polyserine protein species from CAG repeat mRNAs is
frameshifting (Gaspar et al., 2000; Toulouse et al., 2005; Davies
and Rubinsztein, 2006; Stochmanski et al., 2012). We have
observed thatMID1 induces translation of polyglutamine protein
in a CAG repeat-length dependent manner. Future studies will
show if MID1 also induces translation of protein species from the
other frames like polyalanine or polyserine proteins.
To date, no effective drug that either prevents or slows
progression of the polyglutamine diseases is available and current
treatments are of palliative nature only. An ideal therapeutic
approach should aim at reducing the level of the disease-causing
polyglutamine protein. We have identified the MID1-protein
as a regulator of translation of several polyglutamine proteins.
Our data suggest that targeting MID1 to inhibit translation
of pathogenic polyglutamine proteins could be a therapeutic
approach. However, additional studies in cell line models as well
as preclinical trials are needed to confirmMID1 as a putative drug
target for polyglutamine diseases.
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online at: http://journal.frontiersin.org/article/10.3389/fncel.
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Supplementary Figure 1 | In silico prediction of secondary RNA structures.
The folding of ATXN2, ATXN3 and ATXN7 RNA-constructs used in this study into
secondary structures was predicted using mfold software. (A), (C), and (E)
prediction of ATXN2, ATXN3 and ATXN7 RNA secondary structures with normal
CAG repeat lengths. (B), (D), and (F) prediction of ATXN2, ATXN3 and ATXN7
RNA secondary structures with mutant CAG repeat length. The CAG repeat
region, which folds into a hairpin structure is labeled in red and repeat numbers
are given.
Supplementary Figure 2 | Pictures of an exemplary FRAP experiment. An
example of a cell in the FRAP based translation assay is shown. HeLa cells were
transfected with GFP-ATXN2 with mutant CAG repeats. The seven pictures show
different time points from pre-bleach up to 235 min after bleaching. The increase
in GFP intensity after the bleaching (t = 0) reflects the translation of new protein.
Supplementary Table 1 | ATXN2, ATXN3, and ATXN7-constructs. The
sequences of the fragments of ATXN2, ATXN3, and ATXN7 normal and mutant
that were cloned into the reporter plasmids and were used in this study are shown.
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